NASDAQ: KTTAPasithea Therapeutics Corp Stock Ownership - Who owns Pasithea Therapeutics?
Insider buying vs selling
Have Pasithea Therapeutics Corp insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Simon Dumesnil | Director | 2025-11-28 | 33,333 | $0.75 | $25.00kBuy |
| Emer Leahy | Director | 2025-11-28 | 33,333 | $0.75 | $25.00kBuy |
| Tiago Marques | Chief Executive Officer | 2025-11-28 | 33,333 | $0.75 | $25.00kBuy |
| Daniel H. Schneiderman | Chief Financial Officer | 2025-11-28 | 26,667 | $0.75 | $20.00kBuy |
| Lawrence Steinman | Director | 2025-11-28 | 133,333 | $0.75 | $100.00kBuy |
| Tiago Marques | Chief Executive Officer | 2025-05-12 | 960 | $0.83 | $792.00Sell |
KTTA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when KTTA insiders and whales buy or sell their stock.
KTTA Shareholders
What type of owners hold Pasithea Therapeutics Corp stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Pd Joint Holdings LLC Series 2016a | 10.46% | 2,608,696 | $2.01M | Insider |
| Adage Capital Partners GP LLC | 8.42% | 2,100,000 | $1.62M | Institution |
| Vivo Capital LLC | 8.42% | 2,100,000 | $1.62M | Institution |
| Janus Henderson Group PLC | 8.42% | 2,100,000 | $1.62M | Institution |
| Squadron Capital Management LLC | 8.42% | 2,100,000 | $1.62M | Institution |
| Ameriprise Financial Inc | 7.74% | 1,930,128 | $1.49M | Institution |
| Eric Shahinian | 7.17% | 1,788,415 | $1.38M | Insider |
| Israel Maxx Abramowitz | 4.22% | 1,051,575 | $809.71k | Insider |
| Avi Geller | 4.15% | 1,034,702 | $796.72k | Insider |
| Dean Lazer | 3.62% | 902,600 | $695.00k | Insider |
KTTA vs Biotech Stocks
Pasithea Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.